Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 11.
Article
Ali, A;
Plus 12 other authors, TPUWPO;
Sydes, M;
Clarke, NW;
(2020)
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”.
European Urology Oncology
, 3
(4)
pp. 412-419.
10.1016/j.euo.2020.05.003.
|
 |
|
Cho, G;
Anie, KA;
Buckton, J;
Kiilu, P;
Layton, M;
Alexander, L;
Hemmaway, C;
... Meredith, S; + view all
(2016)
SWIM (sickle with ibuprofen and morphine) randomised controlled trial fails to recruit: lessons learnt.
BMJ OPEN
, 6
(6)
10.1136/bmjopen-2016-011276.
|
|
Clarke, NW;
Ali, A;
Ingleby, FC;
Hoyle, A;
Amos, CL;
Attard, G;
Brawley, CD;
... STAMPEDE investigators; + view all
(2020)
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
[Corrigendum].
Annals of Oncology
, 31
(3)
p. 442.
10.1016/j.annonc.2020.01.002.
|
|
|
Clarke, NW;
Ali, A;
Ingleby, FC;
Hoyle, A;
Amos, CL;
Attard, G;
Brawley, CD;
... James, ND; + view all
(2019)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Annals of Oncology
10.1093/annonc/mdz396.
(In press).
|
|
James, ND;
de Bono, JS;
Spears, MR;
Clarke, NW;
Mason, MD;
Dearnaley, DP;
Ritchie, AWS;
... STAMPEDE Investigators; + view all
(2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
The New England Journal of Medicine
, 377
pp. 338-351.
10.1056/NEJMoa1702900.
|
|
James, ND;
Sydes, MR;
Clarke, NW;
Mason, MD;
Dearnaley, DP;
Spears, MR;
Ritchie, AW;
... STAMPEDE investigators; + view all
(2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet
, 387
(10024)
pp. 1163-1177.
10.1016/S0140-6736(15)01037-5.
|
|
Morrell, L;
Hordern, J;
Brown, L;
Sydes, MR;
Amos, CL;
Kaplan, RS;
Parmar, MKB;
(2019)
Mind the gap? The platform trial as a working environment.
Trials
, 20
(1)
, Article 297. 10.1186/s13063-019-3377-5.
|
|
|
Parker, CC;
James, ND;
Brawley, CD;
Clarke, NW;
Hoyle, AP;
Ali, A;
Ritchie, AWS;
... Systemic Therapy for Advanced or Metastatic Prostate cancer, .; + view all
(2018)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
, 392
(10162)
pp. 2353-2366.
10.1016/S0140-6736(18)32486-3.
|
|
|
Schiavone, F;
Bathia, R;
Letchmanan, K;
Masters, L;
Amos, C;
Bara, A;
Brown, L;
... Sydes, MR; + view all
(2019)
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Trials
, 20
, Article 264. 10.1186/s13063-019-3216-8.
|
|
Sydes, MR;
(2018)
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Annals Of Oncology
, 29
(5)
pp. 1235-1248.
10.1093/annonc/mdy072.
|
|
|
Sydes, MR;
Parmar, MK;
Mason, MD;
Clarke, NW;
Amos, C;
Anderson, J;
de Bono, J;
... James, ND; + view all
(2012)
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.
Trials
, 13
, Article 168. 10.1186/1745-6215-13-168.
|
 |
